"CZ - \u010Cesk\u00E1 republika" . . . "Chronic lymphocytic leukemia (CLL) is a clonal disease of B lymphocyte with extremly variabile course and prognosis. From biological point of view it is a heterogenneic disorder resulting from the imbalance between proliferation activity of the clone and apoptosis. Clinical staging and indication for the therapy initiation is stable for years, however, peognostic factors assessment is usefull during the management and follow up of patients with CLL. New therapeutic approaches were developed during past years. A combination of chemotherapy and immunotherapy represents the most used strategy in the tratment of CLL having influence on major variables in CLL, including quality of life. This success is associated with certain economical burden, therefore the intensive treatment should be guided by an experienced haematooncology center."@en . "leukemia, mutation state, chemotherapy, imunotherapy, remission, minimal residual disease"@en . . "[F8055D401BAF]" . . . "2" . . "P(NR9186)" . "Chronick\u00E1 lymfocit\u00E1rn\u00ED leukemie (LCC) je klon\u00E1ln\u00ED onemocn\u011Bn\u00ED B lymfocyt\u016F s extremn\u011B variabiln\u00EDm pr\u016Fb\u011Bhem a progn\u00F3zou. Biologicky jde tedy o heterogenn\u00ED onemocn\u011Bn\u00ED z nerovnov\u00E1hy proliferace a apopt\u00F3zy malign\u00EDch lymfocyt\u016F. Z\u00E1kladn\u00ED staging a indikace k zah\u00E1jen\u00ED terapie se \u0159adu let nem\u011Bn\u00ED, av\u0161ak stanoven\u00ED prognostick\u00FDch faktor\u016F m\u016F\u017Ee b\u00FDt dobrou orientac\u00ED pro sledov\u00E1n\u00ED pacienta a l\u00E9\u010Debnou strategii. Pomoc\u00ED nov\u00FDch l\u00E9\u010Debn\u00FDch postup\u016F zalo\u017Een\u00FDch na kombinaci chemoterapie a imunoterapie je mo\u017En\u00E9 ve velk\u00E9 m\u00ED\u0159e navodit dlouhotrvaj\u00EDc\u00ED kompletn\u00ED remisi, ovlivnit celkov\u00E9 p\u0159e\u017Eit\u00ED a kvalitu \u017Eivota. Tyto \u00FAsp\u011Bchy jsou spojeny s ekonomickou n\u00E1ro\u010Dnost\u00ED , proto by l\u00E9\u010Debn\u00E1 strategie u pacient\u016Fs CLL m\u011Bla b\u00FDt \u0159\u00EDzena zku\u0161en\u00FDmi hematoonkologick\u00FDmi centry." . . . "1"^^ . . . "Onkologie" . "Chronick\u00E1 lymfocit\u00E1rn\u00ED leukemie (LCC) je klon\u00E1ln\u00ED onemocn\u011Bn\u00ED B lymfocyt\u016F s extremn\u011B variabiln\u00EDm pr\u016Fb\u011Bhem a progn\u00F3zou. Biologicky jde tedy o heterogenn\u00ED onemocn\u011Bn\u00ED z nerovnov\u00E1hy proliferace a apopt\u00F3zy malign\u00EDch lymfocyt\u016F. Z\u00E1kladn\u00ED staging a indikace k zah\u00E1jen\u00ED terapie se \u0159adu let nem\u011Bn\u00ED, av\u0161ak stanoven\u00ED prognostick\u00FDch faktor\u016F m\u016F\u017Ee b\u00FDt dobrou orientac\u00ED pro sledov\u00E1n\u00ED pacienta a l\u00E9\u010Debnou strategii. Pomoc\u00ED nov\u00FDch l\u00E9\u010Debn\u00FDch postup\u016F zalo\u017Een\u00FDch na kombinaci chemoterapie a imunoterapie je mo\u017En\u00E9 ve velk\u00E9 m\u00ED\u0159e navodit dlouhotrvaj\u00EDc\u00ED kompletn\u00ED remisi, ovlivnit celkov\u00E9 p\u0159e\u017Eit\u00ED a kvalitu \u017Eivota. Tyto \u00FAsp\u011Bchy jsou spojeny s ekonomickou n\u00E1ro\u010Dnost\u00ED , proto by l\u00E9\u010Debn\u00E1 strategie u pacient\u016Fs CLL m\u011Bla b\u00FDt \u0159\u00EDzena zku\u0161en\u00FDmi hematoonkologick\u00FDmi centry."@cs . "Chronick\u00E1 lymfocyt\u00E1rn\u00ED leukemie"@cs . "RIV/00064173:_____/08:#0000032!RIV10-MZ0-00064173" . "Chronick\u00E1 lymfocyt\u00E1rn\u00ED leukemie" . "1"^^ . . "Koz\u00E1k, Tom\u00E1\u0161" . "Chronic Lymphocytic Leukemia"@en . . "Chronick\u00E1 lymfocyt\u00E1rn\u00ED leukemie"@cs . . . . "RIV/00064173:_____/08:#0000032" . "7"^^ . "Chronick\u00E1 lymfocyt\u00E1rn\u00ED leukemie" . . "1802-4475" . "Chronic Lymphocytic Leukemia"@en . "359912" . . . "3" .